NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free GBIO Stock Alerts $3.66 -0.11 (-2.92%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.59▼$3.9250-Day Range$2.78▼$4.3552-Week Range$0.86▼$6.98Volume91,125 shsAverage Volume215,428 shsMarket Capitalization$243.50 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Generation Bio alerts: Email Address Generation Bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside118.6% Upside$8.00 Price TargetShort InterestBearish3.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.54) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector607th out of 919 stocksPharmaceutical Preparations Industry285th out of 422 stocks 3.2 Analyst's Opinion Consensus RatingGeneration Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneration Bio has only been the subject of 2 research reports in the past 90 days.Read more about Generation Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.61% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Generation Bio has recently increased by 10.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GBIO. Previous Next 1.9 News and Social Media Coverage News SentimentGeneration Bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Generation Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Generation Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.54) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Generation Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About Generation Bio Stock (NASDAQ:GBIO)Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More GBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBIO Stock News HeadlinesMay 17 at 2:10 AM | americanbankingnews.comGeneration Bio Co. Forecasted to Post Q2 2024 Earnings of ($0.21) Per Share (NASDAQ:GBIO)May 16 at 5:48 AM | americanbankingnews.comGeneration Bio (NASDAQ:GBIO) Rating Reiterated by WedbushMay 16 at 4:54 AM | americanbankingnews.comGeneration Bio (NASDAQ:GBIO) Stock Rating Reaffirmed by Needham & Company LLCMay 16 at 3:02 AM | americanbankingnews.comGeneration Bio Co. Forecasted to Post Q1 2025 Earnings of ($0.12) Per Share (NASDAQ:GBIO)May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)May 13, 2024 | investorplace.comGBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | globenewswire.comGeneration Bio Announces Recent Business Highlights and First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comGeneration Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comGeneration Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingApril 2, 2024 | globenewswire.comGeneration Bio to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comGBIO May 2024 7.500 callMarch 16, 2024 | finance.yahoo.comGBIO Apr 2024 5.000 callMarch 8, 2024 | finance.yahoo.comGeneration Bio Co Reports Full Year and Q4 2023 Financial OutcomesMarch 7, 2024 | finanznachrichten.deGeneration Bio Co.: Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comGBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comGeneration Bio to Present at the 2024 TD Cowen Health Care ConferenceFebruary 25, 2024 | finance.yahoo.comGeneration Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth PlansFebruary 23, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO), Short Interest ReportFebruary 21, 2024 | investing.comGeneration Bio Co (GBIO)February 21, 2024 | msn.comWhat Is Biohacking And Why Gen Z And Millennials Are Obsessed With ItFebruary 6, 2024 | bizjournals.comGeneration Bio ends Waltham lease but landlord fights backFebruary 3, 2024 | msn.comGeneration Bio Co. Ends Lease Citing Landlord BreachJanuary 30, 2024 | msn.comThe booming business of discovering your biological age: This tech company will measure it starting at $400 per yearJanuary 19, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO) Dividends: History, Yield and DatesSee More Headlines Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GBIO CUSIPN/A CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+118.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,610,000.00 Net Margins-1,696.87% Pretax Margin-1,696.87% Return on Equity-82.33% Return on Assets-46.73% Debt Debt-to-Equity RatioN/A Current Ratio8.01 Quick Ratio6.83 Sales & Book Value Annual Sales$5.90 million Price / Sales41.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book1.85Miscellaneous Outstanding Shares66,530,000Free Float52,491,000Market Cap$243.50 million OptionableOptionable Beta2.87 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Cameron Geoffrey McDonough M.D. (Age 54)President, CEO & Director Comp: $939.09kDr. Matthew Norkunas M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $611.11kDr. Matthew Stanton Ph.D. (Age 50)Chief Scientific Officer Comp: $654.83kDr. Mark D. Angelino Ph.D. (Age 51)Co-Founder Dr. Robert Kotin Ph.D. (Age 68)Co-Founder Ms. Antoinette Paone M.B.A. (Age 45)M.S., Chief Operating Officer Ms. Yalonda Howze J.D. (Age 51)Chief Legal Officer & Secretary Ms. Jasmin TowerChief Human Resources OfficerDr. Phillip Samayoa Ph.D. (Age 36)Chief Strategy Officer More ExecutivesKey CompetitorsPuma BiotechnologyNASDAQ:PBYIuniQureNASDAQ:QUREFoghorn TherapeuticsNASDAQ:FHTXOvid TherapeuticsNASDAQ:OVIDG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 16,400 shares on 5/17/2024Ownership: 4.255%Jacobs Levy Equity Management Inc.Sold 56,183 shares on 5/16/2024Ownership: 0.049%Bellevue Group AGBought 244,495 shares on 5/15/2024Ownership: 5.808%Baker BROS. Advisors LPBought 371,219 shares on 5/15/2024Ownership: 0.558%Yiheng Capital Management L.P.Bought 191,530 shares on 5/15/2024Ownership: 0.288%View All Insider TransactionsView All Institutional Transactions GBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Generation Bio stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks. What is Generation Bio's stock price target for 2024? 6 brokers have issued 12-month price objectives for Generation Bio's shares. Their GBIO share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 118.6% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts. How have GBIO shares performed in 2024? Generation Bio's stock was trading at $1.65 at the beginning of 2024. Since then, GBIO stock has increased by 121.8% and is now trading at $3.66. View the best growth stocks for 2024 here. When is Generation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GBIO earnings forecast. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.12. The firm earned $2.88 million during the quarter, compared to the consensus estimate of $3.05 million. Generation Bio had a negative trailing twelve-month return on equity of 82.33% and a negative net margin of 1,696.87%. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH). When did Generation Bio IPO? Generation Bio (GBIO) raised $126 million in an IPO on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Generation Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (13.35%), Bellevue Group AG (5.81%), Artal Group S.A. (4.25%), Vanguard Group Inc. (3.87%), Acadian Asset Management LLC (0.72%) and Los Angeles Capital Management LLC (0.57%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GBIO) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.